EBI

What EBI does

EBI, LLC is a Parsippany, New Jersey-based medical device company founded circa 1980 and currently structured as the only pure-play bone growth stimulation business in the world. The company develops five FDA-approved class III medical devices spanning three electrical stimulation modalities: Pulsed Electromagnetic Field (PEMF, 15Hz, FDA 1979), Capacitive Coupling (CC, 60kHz sinusoidal), and Direct Current (DC). Its non-surgical portfolio includes the Biomet EBI Bone Healing System (PEMF), Biomet OrthoPak (CC), and Biomet SpinalPak (CC); the implantable portfolio includes SpF and EBI OsteoGen, both DC-based devices designed for 24-week in-situ therapy. Reported clinical success rates range from 77% (OrthoPak) to 96% (SpF) across the product line.

The business operates a prescription-based, B2B2C distribution model in which physicians (neurosurgeons, orthopedic specialists, podiatrists) and healthcare institutions (hospitals, surgery centers) prescribe or implant devices, while Durable Medical Equipment providers distribute non-surgical units directly to patients. Reimbursement is sourced from Medicare, Medicaid, workers compensation, and commercial payers; EBI supports this with an in-house reimbursement team handling coding, prior authorization and documentation, plus a Patient Advocacy Group for patient-side logistics. The company maintains a domestic-only (United States) footprint, with manufacturing in Guaynabo, Puerto Rico and headquarters in Parsippany, NJ. Following its May 2025 acquisition by Avista Healthcare Partners and the 2026 acquisition of competitor Xstim, EBI is positioned as the largest standalone pure-play in its therapeutic category, treating over 20,000 patients in 2025.

Name

EBI

Legal name

EBI, LLC

Website

https://ebibonestimulator.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

EBI is a pure-play medical device company that develops FDA-approved electrical bone growth stimulators (PEMF, Capacitive Coupling, and Direct Current) for spinal fusions, fracture nonunions, and failed joint fusions, sold via prescription to neurosurgeons, orthopedic specialists, podiatrists, hospitals, surgery centers, and DME providers in the United States.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

Keywords

• Bone growth stimulation
• Spinal fusion devices
• Orthopedic medical devices
• Fracture nonunion treatment
• Electrical bone stimulation

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales - Non-Surgical Bone Growth Stimulators: Sale of FDA-approved non-surgical bone growth stimulation devices including Bone Healing System (PEMF), OrthoPak (Capacitive Coupling), and SpinalPak (Capacitive Coupling). These prescription-only devices are sold to patients through healthcare providers, with insurance reimbursement through Medicare, Medicaid, workers compensation, and commercial healthcare plans.
2. Medical Device Sales - Implantable Bone Growth Stimulators: Sale of FDA-approved implantable bone growth stimulation devices including SpF (Spinal Fusion Stimulator) and OsteoGen (Fracture Nonunion Stimulator). These class III medical devices are surgically implanted during procedures and provide around-the-clock stimulation therapy for 24 weeks.
3. Insurance Reimbursement and Payer Services: Revenue generated through insurance reimbursement from Medicare, Medicaid, workers compensation, and commercial payers. EBI provides benefit verification, prior authorization assistance, appeals support, and ICD-10/CPT coding guidance as part of their payer services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

EBI develops, manufactures, and sells FDA-approved bone growth stimulation medical devices that use electrical fields to assist bone healing in spinal fusions, fracture nonunions, failed joint fusions, and congenital pseudarthrosis. The company offers five products across three electrical stimulation technologies: Pulsed Electromagnetic Field (Bone Healing System), Capacitive Coupling (OrthoPak, SpinalPak), and Direct Current implantable devices (SpF, OsteoGen). Devices are prescription-only and sold to healthcare providers, hospitals, surgery centers, and Durable Medical Equipment providers with insurance reimbursement through Medicare, Medicaid, workers compensation, and commercial payers.

Product overview

EBI offers a complete portfolio of bone growth stimulation products consisting of both non-invasive and implantable medical devices. The non-surgical portfolio includes the Biomet® EBI® Bone Healing System (PEMF technology), Biomet® OrthoPak® (Capacitive Coupling), and Biomet® SpinalPak® (Capacitive Coupling). The implantable portfolio includes SpF® Implantable Spinal Fusion Stimulators and EBI® OsteoGen™ (both using Direct Current technology). These products work through distinct electrical stimulation technologies—PEMF, Capacitive Coupling, and Direct Current—to promote bone healing in nonunion fractures, failed fusions, and as adjuncts to spinal fusion surgery.

Differentiator

Problem solved

Functional benefit

Brands

• Biomet EBI Bone Healing System: FDA-approved non-invasive bone growth stimulation device using Pulsed Electromagnetic Field (PEMF) technology for treatment of nonunion fractures, failed fusions, and congenital pseudarthrosis.
• Biomet OrthoPak
• Biomet SpinalPak
• SpF Implantable Spinal Fusion Stimulators
• EBI OsteoGen

Products and services

• Biomet EBI Bone Healing System FDA-approved non-invasive bone growth stimulation device using Pulsed Electromagnetic Field (PEMF) technology at 15Hz as adjunctive therapy for nonunion fractures, failed fusions, and congenital pseudarthrosis. Delivers stimulation through flexible treatment coils providing 360-degree coverage.
• Biomet OrthoPak Non-invasive Bone Growth Stimulator System FDA-approved non-invasive bone growth stimulator using 60kHz Capacitive Coupling (CC) technology delivered via Soft-Touch electrodes for treatment of established fracture nonunions.
• Biomet SpinalPak Non-invasive Spine Fusion Stimulator System FDA-approved non-invasive spine fusion stimulator using Capacitive Coupling (CC) technology as adjunctive therapy for lumbar spinal fusion surgery.
• SpF Implantable Spinal Fusion Stimulators FDA-approved class III surgically implanted battery-powered direct current (DC) bone growth stimulation device featuring titanium cathode design, designed to promote bone healing following spinal fusion surgery with constant around-the-clock therapy for 24 weeks.
• EBI OsteoGen Surgically Implanted Bone Growth Stimulators FDA-approved class III surgically implanted battery-powered direct current (DC) bone growth stimulation device (20µA single-lead, 40µA dual-lead) for treatment of fracture nonunions, providing constant around-the-clock therapeutic treatment for 24 weeks.

Quantifiable outcome

• SpF stimulator achieved 96% overall (clinical and radiographic) success rate in instrumented lumbosacral fusions
• +5 more outcomes

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• XstimcoreStrategic or Co-development PartnerEBI acquired Xstim, strengthening its market leadership and reinforcing its position as the only pure-play bone growth stimulation company. The acquisition expands EBI's product portfolio and customer base in the bone growth stimulation market. Xstim was a competitor in the bone growth stimulation space with products including the Xstim Spine Fusion Stimulator.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic's Spine and Biologics division is a global spine surgery leader and a major customer-adjacent player for EBI, since spinal fusion procedures generate demand for EBI's SpF and SpinalPak stimulators. EBI's CEO previously held senior sales leadership at Medtronic Spine and Biologics for nine years.
• Stryker: Stryker is a broad medical device incumbent with deep spine, orthopedic trauma, and surgical franchises that compete with EBI in the operating room channel for implantable bone growth stimulators. Its scale and hospital purchasing relationships shape the broader orthopedic environment in which EBI sells its SpF and OsteoGen devices.
• Globus Medical: Globus Medical (which merged with NuVasive) is one of the largest spine-focused medical device companies, providing fusion hardware and biologics used in the same spinal fusion procedures where EBI's SpF and SpinalPak serve as adjunctive electrical stimulation therapy. Overlap in spine surgeon customer base is substantial.
• Smith+Nephew: Smith+Nephew operates across orthopedic reconstruction, trauma, and sports medicine with a meaningful presence in bone healing adjacencies. While not a direct bone growth stimulator peer, it competes for orthopedic specialist mindshare and DME channel relationships that EBI depends on.
• Zimmer Biomet: Zimmer Biomet is a global orthopedic and surgical implant leader whose "Biomet" brand appears on several EBI product names (Biomet EBI Bone Healing System, Biomet OrthoPak, Biomet SpinalPak). Zimmer Biomet operates broadly in spine, trauma, and reconstructive orthopedics, making it both a former parent and a continuing adjacent incumbent.

Direct peers

• Bioventus: Bioventus competes directly with EBI in the bone healing adjunct category through its EXOGEN ultrasound bone healing system, targeting the same fracture nonunion and fusion indications. Both companies sell through orthopedic specialists, podiatrists, and DME channels with similar reimbursement dynamics.
• Orthofix Medical: Orthofix Medical is the closest direct competitor to EBI in bone growth stimulation, offering Cervical-Stim and Spinal-Stim implantable stimulators as well as the Physio-Stim for nonunions. EBI's new CEO Kevin Kenny was previously President of Global Spine at Orthofix, underscoring the overlap in product portfolio, customer base (spine surgeons), and clinical positioning.
• DJO (Enovis): DJO, now part of Enovis, markets bone growth stimulation products (e.g., CMF OL1000 and related bone healing devices) directly competing with EBI's OrthoPak and SpinalPak capacitive coupling devices. Both sell through orthopedic and podiatric channels with similar DME distribution models.

Others

• B. Braun/Aesculap: B. Braun, through its Aesculap division, provides orthopedic surgical implants and devices used in spinal fusion and trauma procedures. It is an adjacent ecosystem participant rather than a direct stimulator competitor, but EBI's CEO previously held senior sales leadership at B. Braun/McGaw, indicating operational familiarity.

Emerging players

• Collagen Solutions (or other emerging regenerative/biologic bone healing players): Emerging regenerative and biologic bone healing companies (e.g., Regenexx, mesoblast-adjacent therapies, novel BMP formulations) target the same spinal fusion and nonunion indications as EBI's electrical stimulators. These emerging modalities represent a long-term competitive vector that could erode EBI's adjunctive therapy share if clinical evidence matures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EBI